13th Jul 2026 20:05
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Ondine Biomedical Inc - Vancouver-based antimicrobial therapies developer - Topline results from the Lantern phase 3 study evaluating its non-antibiotic nasal photodisinfection technology (branded as Steriwave outside the US) are now expected within around six weeks. The revised timeline reflects recent guidance from the company's independent data management and statistical advisers. This reflects the scale of the study and the normal process of finalising a high-quality analysis dataset and associated documentation in preparation for regulatory submission. The primary endpoint and success criteria remain unchanged. Chief Executive Carolyn Cross says: "Final database activities are progressing well, and we remain focused on reporting topline results as soon as possible. We are encouraged by the progress being made and believe results may be available ahead of the revised schedule. Meanwhile, Ondine continues to expand use of Steriwave in more hospitals and surgical specialities in markets where Steriwave is already approved."
----------
New Frontier Minerals Ltd - Australia-focused critical minerals explorer - Assay results from the May 2026 field programme at the Mt Storm copper prospect in north-west Queensland, Australia, confirm high-grade copper mineralisation at surface, with pit and dump samples returning up to 6.88% copper.
Sequential leach testing confirms high recoveries of the sulphuric acid-soluble copper component, firm adds. New Frontier's geological team will return to site later this month to complete detailed geological mapping, which will assist in the development of any future drill programme at Mt Storm.
Chair Gerrard Hall says the results are an "excellent outcome" and that Mt Storm is emerging as a "compelling target".
----------
Helix Exploration PLC - London-based helium exploration and development company advancing the Rudyard helium project in northern Montana - Completes the USD11 million acquisition of the Keyes helium complex, a strategically located helium purification and liquefaction facility in Oklahoma. The deal was announced earlier this month. The acquisition enables Helix to capture the full "margin from wellhead to liquid delivery, positioning the company as an independent, multi-source US liquefier with both its own production and liquefaction infrastructure," it says. Chief Executive Bo Sears says: "The completion of the Keyes helium complex acquisition is a defining milestone for Helix. It transforms our business from a helium producer into a fully integrated helium company, giving us the rare ability to control the value chain from production through to liquefaction. We have acquired a high-quality, cash-generative strategic asset at a substantial discount to replacement cost, with significant expansion potential and infrastructure that would be exceptionally difficult to replicate today. As one of only a handful of helium liquefaction facilities in the United States, the Keyes Helium Complex positions Helix at the centre of an evolving North American helium market and provides a strong platform to accelerate growth, enhance margins and create long-term value for our shareholders."
----------
Buccaneer Energy PLC - Texas-focused exploration company, previously known as Nostra Terra Oil & Gas - Says the company's current average net production at Pine Mills field in East Texas is around 135 barrels of oil per day, with the asset generating positive free cash flow at current oil prices. This is up from around 54 bopd when the current management team assumed responsibility for Pine Mills mid-2024. This followed a "period of underinvestment and cash-flow misallocation". In May, the Pine Mills and Fouke assets generated USD250,000 in positive net cash flow at realised prices exceeding USD100 per barrel. This continued strengthening of the Texas platform underpins the board's "growing focus on identifying opportunities of materially greater scale." Operating costs have been reduced to "manageable" levels, with general and administrative expenses, comprising principally listing costs and staffing, now running well within the cash generated by the existing production base, allowing the company to "comfortably" service interest on legacy debt obligations, and begin to pay down its outstanding debt, further strengthening its financial position. Continues to maintain a constructive relationship with WAFD Bank, its lending facility provider. Fouke area waterflood programme remains on schedule to commence in the late third quarter of 2026. Chief Executive Paul Welch says progress at Pine Mills has been "substantial and, I believe, underappreciated by the market". Adds: "We inherited an asset in decline and a business carrying significant legacy liabilities. We have stabilised production, invested carefully, brought operating costs to very manageable levels, and made real progress settling the obligations we inherited from prior management - all while continuing to service and now pay down our debt." Buccaneer expects to organically grow average net production towards around 250 bopd in the near term.
----------
Distil PLC - London-based owner of premium alcoholic drinks brands - Says it is moving its UK distribution to Fortitude Drinks from August. Fortitude's group company ICB Drinks currently bottles some of Distil's brands and the new agreement is expected to present production, packaging, logistics and warehousing cost savings. ICB Drinks recently launched a new GBP10 million canning line which will enable Distil to speed up the development of new products, including ready-to-drink. In addition, Distil and Fortitude are exploring opportunities to work more closely in relation to export markets. Both parties believe that there is significant untapped export opportunity for Distil's Blavod, RedLeg and Blackwoods Gin and Vodka brands. Distil and Global Brands have mutually agreed to conclude their UK distribution arrangement, with the agreement concluding amicably.
----------
Genflow Biosciences PLC - London-based biotechnology firm - In an operational update covering the six months ended June 30, Chief Executive Eric Leire says all development programmes are "progressing on schedule without delays". "The first half of 2026 has moved our SIRT6 platform from preclinical promise to a body of clinical, regulatory and commercial evidence. We reported positive interim data from SLAB, then confirmed at the three-month follow-up that the effect is sustained rather than transient. We secured a fully funded delivery collaboration with one of the most established names in LNP technology and broadened our intellectual property position. We enter the second half of the year with non-dilutive funding in place, an expanding partner dialogue in animal health, and further data readouts due on schedule," he says. Genflow expects a "comprehensive" update on remaining SLAB endpoints, including methylation clock and muscle histology data, following trial completion at the end of July, while the GF-1004 six-month efficacy assessment is also due early in the second half. "Genflow's 2026 priorities remain pipeline discipline, capital efficiency and the pursuit of further non-dilutive collaboration agreements that provide external validation of the platform," it says.
----------
By Jeremy Cutler, Alliance News reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Ondine BiomedNew Frontier MineralsHelix ExplorationBuccaneer ErgyDistilGenflow Biosci